A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study

Using medical record data from 200 patients with myelofibrosis in the United Kingdom, researchers determined that, at diagnosis, symptoms and prognostic scores were poorly documented and patient-reported outcome measures were not frequently used. For the majority of patients (53.5%), watch and wait was the first management strategy used, with hydroxycarbamide and ruxolitinib being the most commonly used active treatments. Further, only 5% of patients proceeded to allogeneic transplant.